현재 위치:홈 > 뉴스현황 > Our Events > Preclinical Cardiac ...
저자: 업로드:2017-05-24 조회수:
Cardiac safety assessment is an important factor that all kinds of new drugs must be investigated before entering clinical trials. It is also one of the most important and difficult ones in early clinical research of innovative drugs. During recent years, some of the drugs that have been put into clinical use have received widespread attention from drug safety regulators and drug companies because of their potential cardiac toxicity. As a one-stop pharmaceutical R & D integrated outsourcing service CRO with extensive experience of expert team, Medicilon can provide a multi-level preclinical cardiac safety assessment services from cell to the whole animals.
High Performance Prediction of drug reliability in early cardiac safety pharmacology is particularly important for reducing the potential adverse effects of clinical studies. At present, there are only few one-stop pharmaceutical R & D services CROs in China, which could comply with GLP standard and provide IND filing of cardiac safety assessment. As one of the few of them, the details of Medicilon’s services are as following:
- Cell level detection
Some of the Instruments for Preclinical Cardiac Safety Assessment
Patch Clamp
DSI Full Implanted Telemetry System
DSI JET Vest Telemetry System
- As a one-stop pharmaceutical R & D outsourcing CRO, by providing the information on cardio toxicity assessment in the early period, this could help Medicilon for screening higher cardiac safety factor candidate compound through our chemical, pharmacodynamics, pharmaceutical and preparation services or platforms.
For more information, please refer to the below website.
http://www.medicilon.com/drug-safety-evaluation/Safety-Evaluation.shtml